SCHEMBL10134992

SCHEMBL10134992

CC(C)(C)OC(=O)N1CCC(Nc2nc3cc(C#N)ccc3c3sccc23)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 3/20 0.57
IRAK4 Q9NWZ3 2/20 0.54
GPR119 Q8TDV5 5/20 0.53
CSNK2A1 P68400 2/20 0.51
DNMT3A Q9Y6K1 1/20 0.46
EHMT2 Q96KQ7 2/20 0.45
KDM1A O60341 1/20 0.45
RCOR1 Q9UKL0 1/20 0.45
CETP P11597 1/20 0.44
CCNC P24863 1/20 0.43
CDK8 P49336 1/20 0.43
CLK1 P49759 1/20 0.43
CLK2 P49760 1/20 0.43
CDK7 P50613 1/20 0.43
CDK9 P50750 1/20 0.43
IRAK1 P51617 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
ALDH1A1 P00352 2/20 0.42
PIK3CD O00329 1/20 0.42
CNR1 P21554 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10134874 0.93 NSD2 (0.55) NSD2IRAK4GPR119CSNK2A1DNMT3A
SCHEMBL11932529 0.88 CSNK2A1 (0.54) NSD2IRAK4GPR119CSNK2A1DNMT3A
SCHEMBL10134998 0.83 GBA1 (0.49) NSD2IRAK4GPR119CSNK2A1CETP
SCHEMBL10134997 0.83 CSNK2A1 (0.53) NSD2IRAK4CSNK2A1EHMT2KDM1A
SCHEMBL10135004 0.80 CSNK2A1 (0.41) IRAK4GPR119CSNK2A1CETPL3MBTL1
SCHEMBL10135009 0.79 CSNK2A1 (0.44) IRAK4GPR119CSNK2A1CETPCCNC
SCHEMBL10134993 0.78 CSNK2A1 (0.55) NSD2IRAK4CSNK2A1CDK7CLK4
SCHEMBL10134990 0.77 CSNK2A1 (0.49) NSD2IRAK4CSNK2A1CDK7
SCHEMBL10134995 0.77 ADORA2A (0.45)
SCHEMBL10134947 0.76 CSNK2A1 (0.47) IRAK4CSNK2A1EHMT2CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 NSD2 1799/4885IRAK4 844/4885GPR119 3491/4885
US-20090239859-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 NSD2 1799/4885IRAK4 844/4885GPR119 3491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.